Your Location:
Home >
Browse articles >
Relationship between abnormal characteristics of sublingual collateral and portal vein hemodynamic changes in patients with primary hepatic carcinoma
Updated:2021-08-27
    • Relationship between abnormal characteristics of sublingual collateral and portal vein hemodynamic changes in patients with primary hepatic carcinoma

    • Chinese Journal of Integrative Medicine   Vol. 14, Issue 1, Pages: 28-32(2008)
    • DOI:10.1007/s11655-008-0028-1    

      CLC:
    • Published:2008,

      Published Online:21 June 2008,

    Scan for full text

  • Wei-zhe Deng, Qing-bo Lang, Chang-quan Ling. Relationship between abnormal characteristics of sublingual collateral and portal vein hemodynamic changes in patients with primary hepatic carcinoma. [J]. Chinese Journal of Integrative Medicine 14(1):28-32(2008) DOI: 10.1007/s11655-008-0028-1.

  •  
  •  
FULL TEXT LINK
More>

0

Views

330

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Structural shifts of gut flora in rat acute alcoholic liver injury and Jianpi Huoxue Decoction’s (健脾活血汤) effect displayed by ERIC-PCR fingerprint
Short-term effect of combined therapy with Jinlong Capsule (金龙胶囊) and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression
Study on diagnosis criteria of fire-heat syndrome based on receiver operating characteristic curve and principal component analysis
Antipyretic Effect of Herba Ephedrae-Ramulus Cinnamomi Herb Pair on Yeast-Induced Pyrexia Rats: A Metabolomics Study

Related Author

No data

Related Institution

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Institutes of Shanghai Municipal Education Commission, Shanghai
Key Laboratory of Liver and Kidney Diseases, Ministry of Education
The First Affiliated Hospital, College of Medicine, Zhejiang University
Center for Drug Reevaluation, State Food and Drug Administration
0